TABLE 1.
Comparison of resistance profiles by original phenotypic drug susceptibility testing in 1993 to 1995 and by Genotype MTBDRplus or MTBDRsl on extracted DNA in 2014
| Resistance profile method and druga | No. (%) of resistant isolates |
|
|---|---|---|
| Gauteng Province (n = 120) | Western Cape Province (n = 120) | |
| Phenotypic MDR-TB profile (1993–1995) | ||
| RIF | 120 (100) | 120 (100) |
| INH | 120 (100) | 120 (100) |
| PZA | 42 (35) | 0 |
| EMB | 7 (6) | 35 (29) |
| ETM | 14 (12) | 45 (37) |
| SM | 17 (14) | 45 (37) |
| OFX | 1 (<1) | 1 (<1) |
| KAN | 1 (<1) | 0 |
| Genotypic resistance profile (Genotype MTBDRplus or MTBDRsl LPA) on extracted DNA (2014) | ||
| RIF+INH | 73 (61) | 98 (82) |
| RIF mono | 30 (25) | 14 (12) |
| INH mono | 3 (2) | 2 (2) |
| EMB | 11 (9) | 39 (34) |
| OFX+AMG | 1 (<1)b | 2 (2) |
| OFX mono | 1 (<1)b | 2 (2) |
| Susceptible | 14 (12) | 6 (5) |
a
Abbreviations: RIF, rifampin; INH, isoniazid; EMB, ethambutol; PZA, pyrazinamide; ETM, ethionamide; SM, streptomycin; OFX, ofloxacin; KAN, kanamycin; AMG, aminoglycoside; mono, monoresistant.
b
Of a total of 117 isolates instead of 120.